Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Zenas Biopharma Inc Is A Clinical-Stage Biopharmaceutical Company. Its I&I Product Candidate, Obexelimab, Is A Bifunctional Monoclonal Antibody Designed To Bind Both Cd19 And Fcyriib, Which Are Present Across B Cell Lineage, In Order To Inhibit The Activity Of Cells That Are Implicated In Many Autoimmune Diseases Without Depleting Them. The Company Manages Its Operations On A Consolidated Basis As A Single Reportable Segment Focused On The Research, Development And Commercialization Of Transformative Immunology-Based Therapies.